Dipeptidyl peptidase 9 and thioredoxin are examples of endogenous inhibitors that have been found to interact with NLRP1, raising the prospect of creating small-molecule medications that target NLRP1 to treat neurodegenerative diseases. This evidence concerns the gene NLRP1 and neurodegenerative disease.